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Abstract
Introduction: Understanding whether mammographic density (MD) is associated with all breast tumor subtypes
and whether the strength of association varies by age is important for utilizing MD in risk models.
Methods: Data were pooled from six studies including 3414 women with breast cancer and 7199 without who
underwent screening mammography. Percent MD was assessed from digitized film-screen mammograms using a
computer-assisted threshold technique. We used polytomous logistic regression to calculate breast cancer odds
according to tumor type, histopathological characteristics, and receptor (estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor (HER2)) status by age (<55, 55–64, and ≥65 years).
Results: MD was positively associated with risk of invasive tumors across all ages, with a two-fold increased risk for
high (>51%) versus average density (11-25%). Women ages <55 years with high MD had stronger increased risk of
ductal carcinoma in situ (DCIS) compared to women ages 55–64 and ≥65 years (Page-interaction= 0.02). Among all
ages, MD had a stronger association with large (>2.1 cm) versus small tumors and positive versus negative lymph
node status (P’s< 0.01). For women ages <55 years, there was a stronger association of MD with ER-negative breast
cancer than ER-positive tumors compared to women ages 55–64 and ≥65 years (Page-interaction= 0.04). MD was
positively associated with both HER2-negative and HER2-positive tumors within each age group.
Conclusion: MD is strongly associated with all breast cancer subtypes, but particularly tumors of large size and
positive lymph nodes across all ages, and ER-negative status among women ages <55 years, suggesting high MD
may play an important role in tumor aggressiveness, especially in younger women.
Introduction
Mammographic density (MD) is one of the strongest risk
factors for breast cancer: women in the highest quartile
of MD have four to six times increased risk of breast
cancer compared with those in the lowest quartile [1].
The magnitude of risk associated with established breast
cancer risk factors, such as age, menopausal status, and
parity, differs according to tumor characteristics [2-6],
suggesting breast cancer is a heterogeneous disease that
develops through different pathways and may have etio-
logically distinct tumor subtypes. Because MD is a potential
risk factor for prediction models, understanding whether
MD is a risk factor for all breast cancer subtypes, including
the most aggressive, and whether these associations are
consistent at all ages is highly significant.
To date, the MD and breast cancer association accord-
ing to different tumor characteristics is inconsistent
[7-20]. Some previous analyses report no clear differ-
ences in strength of association by tumor characteristics
[10-12,16-20], while others suggest the association be-
tween MD and breast cancer risk differs by estrogen re-
ceptor (ER) status [13-16], invasiveness [15,21], and
tumor size [7-9]. Most [7-9,15,22], but not all [10], prior
studies have reported stronger associations of MD with
large tumors versus small tumors, which could reflect
delays in diagnosis due to reduced sensitivity of mam-
mography [23] and/or aggressive tumor biology.
Given these conflicting results and known differences
in the tumor biology of younger and older women diag-
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comprehensive pooled analysis of six case–control studies,
two of which were nested within cohorts, to examine risk
of breast cancer associated with MD by age and tumor
characteristics.
Methods
Study populations
Participating studies included the Mayo Mammography
Health Study (MMHS) [27,28], the Mayo Clinic Breast
Cancer Study (MCBCS) [29,30], the Nurses’ Health
Study (NHS) and NHSII [31-33], the Mayo Clinic Mam-
mography Study (MCMAM) [34], and the San Francisco
Bay Area Breast Cancer SPORE and San Francisco
Mammography Registry (SFMR) [35-37] (Table 1; see also
Additional file 1). From all studies, we excluded breast
cancer cases diagnosed within 6 months of mammography
and their matched controls, to minimize prevalent cancers
at the time of mammography. Covariate information
was obtained from medical record review (MCMAM),
self-administered questionnaires (NHS, NHSII), or both
(MMHS, MCBCS), prior to mammography (NHS and
NHSII) or at the time of mammography (MCBCS,
MMHS, MCMAM, and SFMR). In total, these analyses
included 3,414 breast cancer cases and 7,199 controls.
This study was approved by the Institutional Review
Boards at the Mayo Clinic, Brigham and Women’s Hos-
pital, the University of California, San Francisco (UCSF),
and the Connecticut Department of Public Health Hu-
man Investigations Committee. Informed consent was
obtained or implied by return of questionnaires (NHS,
NHSII).
Assessment of mammographic density
MD was measured using two computer-assisted thresh-
old techniques (Cumulus [38] and UCSF custom mam-
mographic density software [39]) from digitized images
of prediagnostic film screening mammograms of the cra-
niocaudal view. With the exception of NHS and NHSII,
for which the average percent MD of both breasts was
used, MD was estimated from the contralateral breast
for cases and the corresponding side for matched con-
trols. Previous studies have documented that similar re-
sults are obtained from an average of both breasts and
from a randomly selected side [40] and the correlation
between the right and left breast MD is 0.96 [41].
Because of known differences in the distribution of
percent MD between readers [42,43], we standardized
MD measurements made within each study (Additional
file 1) for pooled analyses. Briefly, we focused on women
without breast cancer and estimated study-specific linear
age trends in the medians of the logit-transformed MD
values using quantile regression. We removed the study-
specific age trends by computing the difference between
each individual’s observed logit-transformed MD and the
age-predicted median logit-transformed MD from the
corresponding study set. We standardized the variability
across studies by dividing the residuals within each study
by their corresponding interquartile range, and multiplied
these rescaled residual values by the interquartile range of
the original residuals from all studies. This ensured that
the variability in standardized logit-transformed MD was
consistent across studies, and was roughly equivalent to
the observed variability in logit-transformed MD. Finally,
we estimated an overall age by logit-transformed MD
trend from the original data, and added the age-predicted
median logit-transformed MD to the rescaled residuals
from each individual. This incorporated the known age
trend in MD into the standardized logit-transformed
MD measurements. These logit-transformed MD values
were back-transformed to the original scale for use in
analyses.
Assessment of tumor characteristics among cases
Information on tumor type, histology, grade, nodal in-
volvement, tumor size, and ER, progesterone receptor
(PR), and human epidermal growth factor receptor 2
(HER2) status was obtained from state-wide Surveillance
Epidemiology and End Results programs (SFMR), path-
ology reports (NHS and NHSII), state and clinic cancer
registries (MMHS, MCMAM, MCBCS), and medical re-
cords (MMHS, MCMAM, MCBCS). For 66 cases in NHS
or NHSII with missing receptor data on pathology reports,
receptor status was obtained from immunohistochemical
staining performed on paraffin sections of the tumor tis-
sue microarray according to a standard protocol [44]. A
large proportion of cases (39%) were missing HER2 status;
and 31% of cases were diagnosed prior to the availability
of herceptin and the need for HER2 testing, primarily
from the MCMAM and NHS studies that were mostly
postmenopausal cases. Another 2% were cases with bor-
derline HER2 results (2+ without available fluorescent
in situ hybridization) and were not used in analyses.
Statistical analyses
Standardized percent MD was categorized as 0 to 10%,
11 to 25%, 26 to 50%, and 51%+, with the average MD
group (11 to 25%) as the reference group consistent with
previous analyses [17,37]. We fit polytomous (multi-
nomial) logistic regression models to estimate odds ratios
(ORs) and 95% confidence intervals for the associations of
MD with overall breast cancer as well as with breast can-
cer defined by tumor type (invasive or ductal carcinoma
in situ (DCIS)), histologic type (ductal or lobular), grade
(well differentiated, moderately differentiated, or poorly
differentiated), tumor size (<1.1 cm, 1.1 to 2.0 cm, or 2.1+
cm), involvement of lymph nodes (positive or negative),
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Study name
(abbreviation)
Reference Study design Number of
cases/controls
Enrollment
year(s)
Mammogram
film view
Median interval
(years) between
mammogram and
diagnosis (index date)
Source of
cases
Source of pathology Source of
covariate data
Mayo Mammography
Health Study (MMHS)
[27,28] Nested case–
control study
404/1,207 2003 to 2006 CC average 3.6 Linkage to clinic
and state cancer
registries
Clinic and three
state cancer registries;
medical records
Questionnaire
and medical record
review (BMI)
Mayo Clinic Breast
Cancer Study (MCBCS)
[29,30] Case–control
study
261/179 2001 to 2008 CC contralateral 1.3 Clinic Clinic cancer registry;
medical records
Questionnaire and
medical record
review (BMI)
Nurses’ Health
Study (NHS)
[31,33] Nested case–
control study
1,108/2,163 1989 to 1990 CC average 5.2 Self-report Pathology reports
and tumor tissue
microarray
Questionnaire
Nurses’ Health
Study II (NHSII)
[32] Nested case–
control study
365/992 1996 to 1999 CC average 4.2 Self-report Pathology reports
and tumor tissue
microarray
Questionnaire
Mayo Clinic
Mammography
Study (MCMAM)
[34] Case–control
study
372/679 1997 to 2001 CC average 7.1 Clinic Clinic cancer registries;
medical records
Medical record
review
Bay Area Breast
Cancer SPORE and
San Francisco
Mammography
Registry (SFMR)
[35-37] Nested case–
control study
904/1,979 1996 to 2007 CC contralateral 3.1 Linkage to
state-wide
SEER program
SEER Questionnaire
BMI, body mass index; CC, craniocaudal mammogram view; SEER, Surveillance, Epidemiology and End Results.
B
e
r
t
r
a
n
d
e
t
a
l
.
B
r
e
a
s
t
C
a
n
c
e
r
R
e
s
e
a
r
c
h
2
0
1
3
,
1
5
:
R
1
0
4
P
a
g
e
3
o
f
1
3
h
t
t
p
:
/
/
b
r
e
a
s
t
-
c
a
n
c
e
r
-
r
e
s
e
a
r
c
h
.
c
o
m
/
c
o
n
t
e
n
t
/
1
5
/
6
/
R
1
0
4and receptor status (ER-positive or ER-negative, PR-
positive or PR-negative, HER2-positive or HER2-negative).
We pooled data across the six studies and adjusted for
study, age (continuous), and body mass index (continu-
ous) in multivariable models. We further considered po-
tential confounding by parity (nulliparous, parous, or
unknown) and first-degree family history of breast can-
cer (yes, no, or unknown) by evaluating the magnitude
of change in ORs observed after including each potential
confounder individually in the model. Postmenopausal
hormone therapy (current estrogen alone, current estro-
gen plus progesterone, never/former, or unknown) was
also evaluated as a confounder among postmenopausal
women in the subset of studies for which this informa-
tion was available (MMHS, NHS, NHSII, and SFMR).
Addition of these variables to the models did not sub-
stantially change risk estimates and they were not in-
cluded in final models. Results were similar in sensitivity
analyses restricted to Caucasians only (data not shown).
Because prior studies suggest differences in the strength
of the association of MD with breast cancer by age [45],
and since tumor biology varies with age [24-26], analyses
were conducted across all women and stratified by three
a g eg r o u p s( < 5 5y e a r s ,5 5t o6 4y e a r s ,a n d≥65 years) to
best capture these differences. We evaluated whether the
associations between MD and breast cancer differed by
specific tumor characteristics, both overall and within age
group, using polytomous logistic regression models (Pheter-
ogeneity). For subtypes with a natural ordering, including
tumor size and grade, tests of trend (Ptrend) across categor-
ies were used to assess significance. Formal tests of
interaction (Page-interaction) assessed the significance of dif-
ferential MD associations with each of the breast cancer
characteristics and subtypes across the three age groups.
Prior to pooling data across the six studies, study-
specific estimates were obtained by fitting separate models
for each study and assessing individual associations be-
tween MD and each tumor subtype. We assessed the stat-
istical significance of differences in associations by study
through testing for interactions between study group and
MD category in the pooled analysis, and found no evi-
dence of differences across study (all P values >0.29).
Analyses were performed using SAS software (version
9.3; SAS Institute, Cary, NC, USA). All statistical tests were
two-sided and P <0.05 was considered statistically
significant.
Results
Overall, the mean age at mammogram was 57 years
among both cases and controls. The mean time to diag-
nosis was 4.5 years (range: 0.5 to 17.6). Among both
cases and controls, the mean percent MD decreased
with age, but in each age group the mean percent MD
w a sh i g h e ra m o n gc a s e sv e r s u sc o n t r o l s( T a b l e2 ) .D C I S
was more common among younger women compared
with older women, while invasive breast cancers in
women <55 years at mammography generally displayed
more aggressive tumor characteristics compared with
women ≥55 years (Table 3).
Overall and invasive breast cancer and ductal carcinoma
in situ
A positive association of MD with breast cancer overall,
adjusted for age and body mass index, was seen for each
study (Table S1 in Additional file 2). In the pooled ana-
lysis, MD was positively associated with breast cancer
risk overall and with invasive cancer, after adjusting for
study, body mass index, and age, with similar magni-
tudes of effect in each MD category (Table 4). However,
the difference in the magnitude of association of MD
with breast cancer by tumor type (invasive vs. DCIS) var-
ied significantly across age groups (Page-interaction=0. 02 ;
T a b l eS 2i nA d d i t i o n a lf i l e2 ) .T h e r ew e r es i m i l a ra s s o c i a -
tions of MD with invasive breast cancer across age groups
(Figure 1; see also Table S2 in Additional file 2). But the
associations of MD with DCIS differed, primarily for
women aged <55 years compared with those aged ≥55 years.
Younger women with high MD had increased risk of DCIS
(ORs for MD 26 to 50% and 51% + vs. MD 11 to 25% were
1.99 and 2.39, respectively) that was not as strong in older
age groups (corresponding ORs of 1.59 and 1.47 for age
55 to 64, and 1.22 and 0.96 for age ≥65 years) (Figure 1;
see also Table S2 in Additional file 2).
Grade, invasive histology, size and nodal status
MD was similarly associated with breast cancers of vari-
ous grades (Table 4). Further, this association did not
differ when stratified by age group (Page-interaction =0.21)
(Figure 1; see also Table S3 in Additional file 2). MD
was also similarly associated with both ductal and lobu-
lar histology among all ages combined (Table 4). Despite
evidence of heterogeneity in the association by histologic
subtype overall (Pheterogeneity =0.04), the magnitude of
the association was similar within each age group (all
Pheterogeneity ≥0.12) and there was no evidence of signifi-
cant interaction by age (Page-interaction=0.15). Also, higher
MD was positively associated with invasive tumors of all
sizes but the association was stronger for large tumors
(that is, 2.1+ cm) compared with small tumors <1.1 cm
among all women combined (Ptrend <0.01; Table 4) and
within age groups (Figure 1; see also Table S3 in Additional
file 2). The ORs for MD 51% +versus MD 11 to 25%
ranged from 1.33 to 1.61 for invasive tumors <1.1 cm and
from 2.88 to 3.65 for tumors 2.1+ cm. Low MD (that is, 0
to 10%) was not significantly associated with a reduced risk
of tumors <1.1 cm compared with the referent category
M D1 1t o2 5 % ;h o w e v e r ,f o rt u m o r s> 1 . 1c m ,l o wM Dw a s
significantly associated with lower risk (ORs: 0.31 to 0.60)
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associated with both lymph node-positive and lymph
node-negative tumors among all ages combined, with a
stronger association of MD with node-positive than node-
negative tumors (Pheterogeneity <0.01) (Table 4). The MD
association with breast cancer defined by nodal status
was not different by age group (Page-interaction = 0.24), al-
though there was evidence of a stronger association for
node-positive versus node-negative tumors among
women ages ≥65 (Pheterogeneity =0.04).
Estrogen receptor, progesterone receptor and HER2
status
Associations between MD and breast cancer defined by
ER status differed by age group (Page-interaction= 0.04). For
women aged <55 years, a stronger association was observed
for ER-negative disease (OR: 2.84, 95% confidence interval:
1.83, 4.40) versus ER-positive disease (OR: 1.96; 95% confi-
dence interval: 1.56, 2.45) for MD 51% + versus MD 11 to
25% (Pheterogeneity= 0.09), while associations for women
aged ≥55 years were nonstatistically significantly stronger
for ER-positive tumors versus ER-negative tumors. MD
was similarly associated with PR-negative and PR-positive
tumors in all age groups (Page-interaction =0.10 ).Wh ilethere
was evidence of a significant interaction between MD and
breast cancers by HER2 status and age group (Page-interaction=
0.03), MD was positively associated with both HER2-
negative and HER-positive disease in all age groups and
there were no clear patterns of differences in associations
(Figure 1; see also Table S3 in Additional file 2).
Table 2 Baseline characteristics of study population by age
Age <55 years Age 55 to 64 years Age ≥65 years
Cases Controls Cases Controls Cases Controls
N 1,533 3,373 1,021 2,031 860 1,795
Percent mammographic density 40.7 (19.6) 33.6 (20.2) 29.2 (18.0) 23.7 (17.6) 24.8 (17.1) 21.1 (16.2)
Age at mammogram 47.3 (4.5) 47.4 (4.4) 59.4 (2.9) 59.4 (2.9) 71.0 (5.2) 71.2 (5.1)
Age at diagnosis 51.8 (5.6) – 63.8 (4.1) – 75.0 (5.5) –
Body mass index 24.4 (6.5) 25.4 (6.3) 26.1 (7.1) 26.2 (5.6) 25.6 (8.5) 26 (5.6)
Body mass index categories (kg/m
2)
<25 845 (55.1%) 1,902 (56.4%) 438 (42.9%) 964 (47.5%) 322 (37.4%) 849 (47.3%)
25 to 29 432 (28.2%) 831 (24.6%) 332 (32.5%) 642 (31.6%) 262 (30.5%) 602 (33.5%)
30 to 34 130 (8.5%) 352 (10.4%) 138 (13.5%) 275 (13.5%) 151 (17.6%) 221 (12.3%)
35+ 76 (5.0%) 249 (7.4%) 84 (8.2%) 140 (6.9%) 71 (8.3%) 110 (6.1%)
Unknown 50 (3.3%) 39 (1.2%) 29 (2.8%) 10 (0.5%) 54 (6.3%) 13 (0.7%)
Menopausal status
Premenopausal 948 (61.8%) 2,163 (64.1%) 16 (1.6%) 44 (2.2%) 0 (0%) 0 (0%)
Postmenopausal 473 (30.9%) 1,032 (30.6%) 1,001 (98.0%) 1,979 (97.4%) 860 (100%) 1794 (99.9%)
Unknown 112 (7.3%) 178 (5.3%) 4 (0.4%) 8 (0.4%) 0 (0%) 1 (0.1%)
Parity
Nulliparous 294 (19.2%) 638 (18.9%) 130 (12.7%) 249 (12.3%) 114 (13.3%) 235 (13.1%)
Parous 1,145 (74.7%) 2,652 (78.6%) 824 (80.7%) 1,686 (83.0%) 674 (78.4%) 1,428 (79.6%)
Unknown 94 (6.1%) 83 (2.5%) 67 (6.6%) 96 (4.7%) 72 (8.4%) 132 (7.4%)
Postmenopausal hormone therapy
a
Not current user 158 (40.9%) 411 (45.7%) 404 (48.6%) 1030 (58.6%) 361 (57.8%) 1,010 (69.1%)
Current, estrogen 81 (21.0%) 233 (25.9%) 144 (17.3%) 311 (17.7%) 100 (16.0%) 199 (13.6%)
Current, estrogen+progestin 126 (32.6%) 222 (24.7%) 215 (25.9%) 308 (17.5%) 84 (13.4%) 124 (8.5%)
Unknown 21 (5.4%) 34 (3.8%) 68 (8.2%) 108 (6.1%) 80 (12.8%) 129 (8.8%)
Family history
No 1,207 (78.7%) 2,970 (88.1%) 777 (76.1%) 1,719 (84.6%) 627 (72.9%) 1,450 (80.8%)
Yes 256 (16.7%) 384 (11.4%) 210 (20.6%) 292 (14.4%) 190 (22.1%) 332 (18.5%)
Unknown 70 (4.6%) 19 (0.6%) 34 (3.3%) 20 (1.0%) 43 (5.0%) 13 (0.7%)
Data presented as mean (standard deviation) or n (%).
aAmong postmenopausal women in the Mayo Mammography Health Study, the Nurses’ Health Study, the
Nurses’ Health Study II, and the San Francisco Bay Area Breast Cancer SPORE and San Francisco Mammography Registry.
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In this large pooled analysis we confirmed a positive asso-
ciation between MD and breast cancer risk. Women with
high MD (51%+) had an approximately two-fold higher
risk of breast cancer compared with women with MD 11
to 25%, and those with less extensive mammographic
density (0 to 10%) had almost one-half the risk as those
with 11 to 25% MD. This translates to a relative risk of
around four comparing the highest category of MD with
the lowest, similar to prior studies. Our findings suggest
that MD is a risk factor for all histologic/morphologic
subtypes of breast cancer examined, but a stronger risk
Table 3 Distribution of breast cancer cases from six studies by age and tumor characteristics
Tumor type Age <55 years Age 55 to 64 years Age ≥65 years
N % N % N %
Total controls 3,373 68.8 2,031 66.5 1,795 67.6
Total cases 1,533 31.2 1,021 33.5 860 32.4
Invasive 1,227 80.0 858 84.0 760 88.4
In situ 295 19.2 160 15.7 100 11.6
Unknown 11 0.7 3 0.3 0 0.0
Tumor characteristics
Histology
Ductal 988 80.5 654 76.2 545 71.7
Lobular 123 10.0 110 12.8 114 15.0
Mixed 65 5.3 55 6.4 51 6.7
Unknown/Other 51 4.2 39 4.6 50 6.6
Histologic grade
Well differentiated 292 23.8 248 28.9 259 34.1
Moderately differentiated 466 38.0 320 37.3 295 38.8
Poorly differentiated 342 27.9 165 19.2 134 17.6
Unknown 127 10.4 125 14.6 72 9.5
Tumor size
0.1 to 1.0 cm 378 30.8 312 36.7 279 36.7
1.1 to 2.0 cm 496 40.4 330 39.3 299 39.3
2.1+ cm 310 25.3 184 20.7 157 20.7
Unknown 43 3.5 32 3.3 25 3.3
Involvement of lymph nodes
Negative 810 66.0 610 71.1 500 65.8
Positive 347 28.3 192 22.4 148 19.5
Unknown 70 5.7 56 6.5 112 14.7
Estrogen receptor status
Negative 228 18.6 139 16.2 82 10.8
Positive 949 77.3 674 78.6 644 84.7
Borderline/Unknown 50 4.1 45 5.2 34 4.5
Progesterone receptor status
Negative 329 26.8 232 27.0 157 20.7
Positive 844 68.8 580 67.6 566 74.5
Borderline/Unknown 54 4.4 46 5.4 37 4.9
HER2 status
Negative 674 54.9 359 41.8 383 50.4
Positive 142 11.6 63 7.3 65 8.6
Borderline/Unknown 411 33.5 436 50.8 312 41.1
HER2, human epidermal growth factor receptor 2.
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Number of cases Number of controls Odds ratio (95% CI)
a Pheterogeneity
b
Overall breast cancer
0 to 10% 430 1,485 0.65 (0.56, 0.74)
11 to 25% (reference) 872 2,248 1.00 (reference)
26 to 50% 1,379 2,386 1.65 (1.48, 1.84)
51%+ 733 1,080 2.15 (1.88, 2.46)
Invasiveness
Invasive 0.46
0 to 10% 372 1,485 0.66 (0.57, 0.76)
11 to 25% (reference) 730 2,248 1.00 (reference)
26 to 50% 1,129 2,386 1.65 (1.47, 1.86)
51%+ 605 1,080 2.21 (1.92, 2.55)
In situ
0 to 10% 52 1,485 0.54 (0.38, 0.75)
11 to 25% (reference) 139 2,248 1.00 (reference)
26 to 50% 240 2,386 1.60 (1.28, 2.00)
51%+ 124 1,080 1.87 (1.42, 2.48)
Histology
c 0.04
Ductal
0 to 10% 281 1,485 0.66 (0.56, 0.78)
11 to 25% (reference) 556 2,248 1.00 (reference)
26 to 50% 884 2,386 1.66 (1.46, 1.88)
51%+ 466 1,080 2.14 (1.83, 2.51)
Lobular
0 to 10% 44 1,485 0.54 (0.37, 0.78)
11 to 25% (reference) 100 2,248 1.00 (reference)
26 to 50% 119 2,386 1.36 (1.03, 1.80)
51%+ 84 1,080 2.69 (1.93, 3.74)
Histologic grade 0.89
Well differentiated
0 to 10% 107 1,485 0.61 (0.47, 0.77)
11 to 25% (reference) 228 2,248 1.00 (reference)
26 to 50% 295 2,386 1.41 (1.17, 1.70)
51%+ 169 1,080 2.12 (1.68, 2.67)
Moderately differentiated
0 to 10% 146 1,485 0.69 (0.56, 0.86)
11 to 25% (reference) 270 2,248 1.00 (reference)
26 to 50% 430 2,386 1.70 (1.44, 2.02)
51%+ 232 1,080 2.31 (1.87, 2.84)
Poorly differentiated
0 to 10% 75 1,485 0.65 (0.48, 0.87)
11 to 25% (reference) 148 2,248 1.00 (reference)
26 to 50% 273 2,386 1.90 (1.53, 2.35)
51%+ 143 1,080 2.34 (1.80, 3.04)
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(Continued)
Tumor size <0.001
<1.1 cm
0 to 10% 179 1,485 0.93 (0.76, 1.14)
11 to 25% (reference) 265 2,248 1.00 (reference)
26 to 50% 353 2,386 1.37 (1.15, 1.63)
51%+ 172 1,080 1.61 (1.29, 2.01)
1.1 to 2.0 cm
0 to 10% 121 1,485 0.54 (0.43, 0.67)
11 to 25% (reference) 294 2,248 1.00 (reference)
26 to 50% 453 2,386 1.64 (1.39, 1.93)
51%+ 253 1,080 2.27 (1.86, 2.77)
2.1+ cm
0 to 10% 56 1,485 0.42 (0.30, 0.57)
11 to 25% (reference) 154 2,248 1.00 (reference)
26 to 50% 280 2,386 2.07 (1.67, 2.57)
51%+ 159 1,080 3.12 (2.41, 4.04)
Involvement of lymph nodes 0.01
Negative
0 to 10% 257 1,485 0.67 (0.57, 0.79)
11 to 25% (reference) 508 2,248 1.00 (reference)
26 to 50% 744 2,386 1.54 (1.35, 1.76)
51%+ 406 1,080 2.07 (1.76, 2.44)
Positive
0 to 10% 65 1,485 0.52 (0.38, 0.70)
11 to 25% (reference) 157 2,248 1.00 (reference)
26 to 50% 298 2,386 1.99 (1.61, 2.45)
51%+ 164 1,080 2.67 (2.07, 3.44)
Estrogen receptor status 0.66
Negative
0 to 10% 48 1,485 0.61 (0.43, 0.88)
11 to 25% (reference) 106 2,248 1.00 (reference)
26 to 50% 192 2,386 1.79 (1.39, 2.30)
51%+ 102 1,080 2.18 (1.61, 2.96)
Positive
0 to 10% 305 1,485 0.65 (0.56, 0.77)
11 to 25% (reference) 596 2,248 1.00 (reference)
26 to 50% 880 2,386 1.60 (1.41, 1.82)
51%+ 479 1,080 2.22 (1.9, 2.60)
Progesterone receptor status 0.10
Negative
0 to 10% 90 1,485 0.65 (0.50, 0.85)
11 to 25% (reference) 187 2,248 1.00 (reference)
26 to 50% 288 2,386 1.59 (1.30, 1.94)
51%+ 151 1,080 1.99 (1.56, 2.55)
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positive (vs. node-negative) disease among all women.
We found differential associations of MD and breast
cancer defined by tumor type (DCIS vs. invasive cancer),
ER status and HER2 status, by age group (<55 years, 55
to 64 years and ≥65 years).
Most previous studies of the association between MD
and breast cancer tumor characteristics have focused on
hormone receptor status, with somewhat conflicting re-
sults [9-11,13-17,20,37,46,47] – in part because most
studies have not examined associations by age group
and/or menopausal status. Several studies, including a
recent meta-analysis [19], reported no difference in asso-
ciations between MD and breast cancer by ER status
[9,10,19,20,37,46,47], while others reported stronger as-
sociations for ER-positive disease [13,14,18]. In contrast,
a significantly stronger effect of MD on postmenopausal
breast cancer was reported for ER-negative compared
with ER-positive tumors among the NHS cohort, but the
number of ER-negative cases was small [15]. Findings
from the current pooled analysis stratified by age group,
which included women in the NHS [15], suggest that
MD is more strongly associated with ER-negative breast
cancer (vs. ER-positive) among women <55 years old
compared with women aged 55 years and older. Like
other studies [37], we found no difference in associations
by PR status; however, one recent case-only study found
that tumors diagnosed in women with denser breasts were
more likely to be PR-positive compared with tumors in
women with more fatty breasts [18]. Our findings of MD
positively associated with both HER2-negative and HER2-
positive tumors within age groups are consistent with
prior studies [11,15,19,20], including a meta-analysis of
studies that did not show MD differentially associated by
tumors defined by HER2 across all ages combined [19].
The significant interaction between MD, HER2 status, and
age that we observed may have been influenced by small
numbers of HER2-positive tumors in older age groups
and/or due to chance. In addition, HER2 status was un-
known for a moderate portion of cases, with the primary
reason being a diagnosis date prior to when HER2 was
clinically tested. Since the two older studies were com-
prised of postmenopausal cases, it is not surprising that
we found those without HER2 more likely to be older and
slightly more likely to be node-negative (80% of cases with
unknown/borderline HER2 status were node-negative vs.
70% of those with known HER2 status). Otherwise, the
majority of tumor characteristics were similar between the
two groups. The results with HER2 will need to be con-
firmed in other studies.
Among women aged <55 years who had high MD, we
noted similar associations for DCIS and invasive breast
cancers. However, we noted a stronger association be-
tween MD and breast cancer for invasive versus DCIS
cancers among women aged 55 to 64 years and ≥65 years.
Three prior studies showed either similar associations of
MD with DCIS [20,48] and invasive breast cancer or
somewhat stronger association for invasive tumors [21],
while Yaghjyan and colleagues reported a significantly
stronger association for in situ versus invasive tumors
Table 4 Associations of categorical mammographic density with breast cancer overall and by morphological subtypes
(Continued)
Positive
0 to 10% 265 1,485 0.66 (0.56, 0.78)
11 to 25% (reference) 512 2,248 1.00 (reference)
26 to 50% 782 2,386 1.65 (1.45, 1.89)
51%+ 424 1,080 2.28 (1.93, 2.68)
HER2 status 0.69
Negative
0 to 10% 189 1,485 0.66 (0.54, 0.80)
11 to 25% (reference) 367 2,248 1.00 (reference)
26 to 50% 560 2,386 1.63 (1.40, 1.90)
51%+ 298 1,080 2.06 (1.70, 2.49)
Positive
0 to 10% 31 1,485 0.62 (0.40, 0.97)
11 to 25% (reference) 62 2,248 1.00 (reference)
26 to 50% 116 2,386 1.94 (1.40, 2.69)
51%+ 60 1,080 2.33 (1.57, 3.45)
CI, confidence interval; HER2, human epidermal growth factor receptor 2.
aAdjusted for age, body mass index, and study.
bTest of heterogeneity in associations by subtype (Ptrend for categories with natural ordering; that is, tumor size and histologic grade).
cMixed and other histology categories are excluded.
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current study had a greater number of DCIS cases (555
vs. ≤300) and stratified associations by three age groups.
In fact, when we examined the association of MD and
tumor type overall, we found no difference in the associ-
ation by DCIS versus invasive cancer, underscoring the
importance of examining age-specific associations.
Our findings of stronger associations between MD and
large compared with small tumors within each age group
are consistent with most prior studies [7-9,15,22]. In
addition, we noted a stronger association between MD
and tumors with lymph node involvement compared
with node-negative tumors. Both of these associations
are consistent with studies that have reported positive
associations with MD and breast cancers with aggressive
tumor characteristics, including positive lymph nodes
and advanced stage [7-9,49]. However, we found no evi-
dence of differential associations by tumor grade. Obser-
vations of stronger associations between MD and more
advanced tumors (for example, large size, node-positive)
could perhaps reflect a possible masking effect because
of reduced mammographic sensitivity and consequent
delay in diagnosis [20,22,23]. The mean time between
mammography and diagnosis was 4.6 years, and many of
these women were screened annually, reducing the pos-
sible influence of a masking effect. While we observed a
slightly stronger association between MD and lobular
(vs. ductal) breast tumors among all women, this was
not as apparent in age-stratified analyses and is in contrast
to previous studies, which reported similar associations by
histology [10,12,18].
Taken together, our findings suggest that MD is a risk
factor for all types of breast cancer. However, some dif-
ferences in magnitudes of risk associated with MD were
noted for specific tumor characteristics primarily related
to detection (for example, tumor size and nodal involve-
ment in women of all ages) and for tumor characteristics
primarily related to tumor biology (tumor type in older
women and ER status in younger women). These observa-
tions point to possible heterogeneity by tumor characteristics
Figure 1 Pooled associations of categorical mammographic density for tumor type and morphological subtypes of invasive breast
cancer by age. Odds ratios and 95% confidence intervals adjusted for age, body mass index, and study are shown for each category of
mammographic density (MD): 1, 0 to 10% MD; 2, 11 to 25% MD (reference); 3, 26 to 50% MD; 4, 51%+ MD). (A) Tumor type. (B) Histology.
(C) Tumor grade. (D) Tumor size. (E) Lymph node involvement. (F) Estrogen receptor (ER) status. (G) Progesterone receptor (PR) status. (H) Human
epidermal growth factor receptor 2 (HER2) status. DCIS, ductal carcinoma in situ.
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studies, provide insight into the biological mechanisms by
which MD differentially influences cancer risk.
Some limitations to this study are worth noting. We
pooled data from six different studies, which varied in
study design, population characteristics, geography, and
calendar year. Our study used clinical pathology informa-
tion and not centralized pathology review. In addition,
there may have been changes in diagnostic criteria over
time (for example, differences in threshold for positivity
f o rE Rs t a t u so rH E R 2t e s t i n g ) .F o re x a m p l e ,s o m eo ft h e
earliest diagnoses from the NHS included in this analysis
were from the early 1990s before fluorescent in situ
hybridization testing was routine. However, we found no
evidence of between-study heterogeneity in our results.
Further, any differences would be expected to attenu-
ate associations with MD. The majority of women in
our study were Caucasian; therefore, our findings may
not be generalizable to non-Caucasians. Finally, we
lacked data on the detection method (for example,
screening-detected vs. interval-detected cancer), which
could have helped to clarify the extent to which our ob-
servations reflect delays in diagnosis or tumor biology.
Strengths of the study included the sample of over
3,400 breast cancer cases, providing sufficient statistical
power to examine associations by age group; cases and
controls (except MCBCS) selected from underlying pro-
spective cohort studies or registries with a mean time
between mammogram and breast cancer diagnosis of
4.6 years; and comparable estimates of percent MD
across readers at the three study sites with demonstrated
high intra-reader reliability (intraclass correlation =0.91
to 0.97) and standardization of percent MD for pooled
analyses. The lack of between-study heterogeneity fur-
ther suggests that pooling these data is appropriate.
Also, we had detailed information on tumor characteris-
tics from pathology reports supplemented with informa-
tion from tissue microarrays. Finally, all mammograms
were screening in nature.
Conclusion
We observed significant positive associations between
MD and breast cancer risk across tumor characteristics
and age groups. In addition, we noted stronger associa-
tions for tumors of large size and positive lymph nodes
across all ages, and ER-negative status among women
aged <55 years, suggesting that high MD may play an
important role in tumor aggressiveness, especially in
younger women. Understanding similarities and differ-
ences in etiologic pathways according to breast cancer
tumor characteristics and age has important implications
for development of risk models and tailored primary
prevention. Incorporating MD and traditional breast
cancer risk factors into risk prediction models overall
and into models unique to subtype may improve their
predictive ability and allow clinicians to identify women
at increased risk of breast cancer for targeted prevention
efforts. Moreover, because MD itself is a potentially
modifiable risk factor [50], understanding how it is dif-
ferentially associated with breast cancer subtypes by age,
particularly subtypes with poor prognosis more com-
monly diagnosed in younger women, could lead to novel
strategies to reduce breast cancer incidence.
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